VANGUARD GROUP INC 13D and 13G filings for Sangamo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 4:53 pm Unchanged | 2024-09-30 | 13G | Sangamo Therapeutics, Inc. SGMO | VANGUARD GROUP INC | 9,597,642 4.600% | 0 (Unchanged) | Filing |
| 2024-11-04 1:54 pm Sale | 2024-09-30 | 13G | Sangamo Therapeutics, Inc. SGMO | VANGUARD GROUP INC | 9,597,642 4.600% | -3,001,352 (-23.82%) | Filing |
| 2024-02-13 5:13 pm Sale | 2023-12-29 | 13G | Sangamo Therapeutics, Inc. SGMO | VANGUARD GROUP INC | 12,598,994 7.100% | -1,446,615 (-10.30%) | Filing |
| 2023-02-09 11:32 am Purchase | 2022-12-30 | 13G | Sangamo Therapeutics, Inc. SGMO | VANGUARD GROUP INC | 14,045,609 8.570% | 4,705,054 (+50.37%) | Filing |
| 2022-02-10 08:37 am Purchase | 2021-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | VANGUARD GROUP INC | 9,340,555 6.410% | 886,897 (+10.49%) | Filing |
| 2021-02-10 11:52 am Sale | 2020-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO | VANGUARD GROUP INC | 8,453,658 5.980% | -34,846 (-0.41%) | Filing |